Patents by Inventor Robert J. Cherney
Robert J. Cherney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167131Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.Type: ApplicationFiled: February 11, 2021Publication date: June 1, 2023Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo
-
Patent number: 11524959Abstract: The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.Type: GrantFiled: August 7, 2019Date of Patent: December 13, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Anurag S. Srivastava, Robert J. Cherney, Khehyong Ngu
-
Patent number: 10934286Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: October 12, 2017Date of Patent: March 2, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Qingjie Liu, T. G. Murali Dhar, Lan-ying Qin, Lyndon A. M. Cornelius, Hai-Yun Xiao, Jianqing Li, Robert J. Cherney
-
Patent number: 10711020Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: March 7, 2019Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Publication number: 20190300523Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: October 12, 2017Publication date: October 3, 2019Inventors: Qingjie LIU, T.G. Murali Dhar, Lan-ying Qin, Lyndon A.M. Cornelius, Hai-Yun Xiao, Jianqing Li, Robert J. Cherney
-
Publication number: 20190241588Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: March 7, 2019Publication date: August 8, 2019Inventors: Jingwu DUAN, T.G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Patent number: 10273259Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: September 12, 2017Date of Patent: April 30, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Patent number: 10214537Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: GrantFiled: October 21, 2015Date of Patent: February 26, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Douglas G. Batt, Robert J. Cherney, Lyndon A. M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
-
Patent number: 10023576Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: GrantFiled: October 21, 2015Date of Patent: July 17, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A. M. Cornelius, T. G. Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino
-
Publication number: 20180002358Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 12, 2017Publication date: January 4, 2018Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Publication number: 20170355707Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: ApplicationFiled: October 21, 2015Publication date: December 14, 2017Inventors: Rajeev S. Bhide, Douglas G. Batt, Robert J Cherney, Lyndon A.M. Cornelius, Qingjie Liu, David Marcoux, James Neels, Michael A. Poss, Zheming Ruan, Qing Shi, Anurag S. Srivastava, Lan-ying Qin, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20170355698Abstract: Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.Type: ApplicationFiled: October 21, 2015Publication date: December 14, 2017Inventors: Rajeev S. Bhide, Zheming Ruan, Robert J. Cherney, Lyndon A.M. Cornelius, T.G.Murali Dhar, Hua Gong, David Marcoux, Michael A. Poss, Lan-ying Qin, Qing Shi, Joseph A. Tino
-
Patent number: 9815859Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: May 6, 2016Date of Patent: November 14, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Publication number: 20160326195Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Patent number: 9216972Abstract: Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: October 29, 2010Date of Patent: December 22, 2015Assignee: Bristol-Myers Squibb CompanyInventors: T. G. Murali Dhar, Hai-Yun Xiao, Scott Hunter Watterson, Soo S. Ko, Alaric J. Dyckman, Charles M. Langevine, Jagabandhu Das, Robert J. Cherney
-
Patent number: 8906920Abstract: The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.Type: GrantFiled: November 27, 2013Date of Patent: December 9, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Percy H. Carter, Robert J. Cherney
-
Patent number: 8835470Abstract: Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: April 21, 2011Date of Patent: September 16, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Robert J. Cherney, Yanlei Zhang
-
Publication number: 20140088109Abstract: The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin -1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: Bristol-Myers Squibb CompanyInventors: Percy H. Carter, Robert J. Cherney
-
Patent number: 8642622Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.Type: GrantFiled: June 15, 2011Date of Patent: February 4, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Robert J. Cherney, John V. Duncia, Daniel S. Gardner, Joseph B. Santella, Zhongyu Wang
-
Patent number: 8629282Abstract: Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: W is CH2 or O; Q is Formula (II), Formula (III) or Formula (IV); and R1, R2, R3, R4, n, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: November 2, 2011Date of Patent: January 14, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Robert J. Cherney, Zhongyu Wang